Deficiency of a Β-arrestin-2 signal complex contributes to insulin resistance

Nature

Volumn 457, Issue 7233, 2009, Pages 1146-1149

  Luan, Bing ^a   Zhao, Jian ^a   Wu, Haiya ^c   Duan, Baoyu ^a   Shu, Guangwen ^a   Wang, Xiaoying ^d   Li, Dangsheng ^b   Jia, Weiping ^c   Kang, Jiuhong ^a   Pei, Gang ^a,e  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^d ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^e TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN 2; INSULIN; INSULIN RECEPTOR; PROTEIN KINASE B; SCAFFOLD PROTEIN; STEROID RECEPTOR COACTIVATOR 1;

DIABETES; HEALTH IMPACT; PATHOGEN; PROTEIN; PUBLIC HEALTH; SUBSTRATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DISEASE COURSE; DISEASE EXACERBATION; DOWN REGULATION; IN VIVO CULTURE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; SIGNAL TRANSDUCTION;

ANIMALS; ARRESTINS; CELL LINE; CELL LINE, TUMOR; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; INSULIN; INSULIN RESISTANCE; MICE; MICE, KNOCKOUT; MUTATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

MUS;

EID: 61349130027     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature07617     Document Type: Article

References (26)

1. Matthaei, S., Stumvoll, M., Kellerer, M. & Haring, H. U. Pathophysiology and pharmacological treatment of insulin resistance. Endocr. Rev. 21, 585-618 (2000).
2. Taniguchi, C. M., Emanuelli, B. & Kahn, C. R. Critical nodes in signalling pathways: insights into insulin action. Nature Rev. Mol. Cell Biol. 7, 85-96 (2006).
3. Sun, X. J. et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352, 73-77 (1991).
4. Biddinger, S. B. & Kahn, C. R. From mice to men: insights into the insulin resistance syndromes. Annu. Rev. Physiol. 68, 123-158 (2006).
5. Franke, T. F. et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81, 727-736 (1995).
6. Burgering, B. M. & Coffer, P. J. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376, 599-602 (1995).
7. McDonald, P. H. et al. β-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science 290, 1574-1577 (2000).
8. Luttrell, L. M. et al. Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc. Natl Acad. Sci. USA 98, 2449-2454 (2001).
9. Luttrell, L. M. et al. β-arrestin-dependent formation of β2 adrenergic receptor-Src protein kinase complexes. Science 283, 655-661 (1999).
10. Beaulieu, J. M. et al. An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122, 261-273 (2005).
11. Beaulieu, J. M. et al. A β-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132, 125-136 (2008).
12. Yang, Q. et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436, 356-362 (2005).
13. Chen, R. et al. Regulation of Akt/PKB activation by tyrosine phosphorylation. J. Biol. Chem. 276, 31858-31862 (2001).
14. Jiang, T. & Qiu, Y. Interaction between Src and a C-terminal proline-rich motif of Akt is required for Akt activation. J. Biol. Chem. 278, 15789-15793 (2003).
15. Craxton, A., Jiang, A., Kurosaki, T. & Clark, E. A. Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase Akt. J. Biol. Chem. 274, 30644-30650 (1999).
16. Wong, B. R. et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol. Cell 4, 1041-1049 (1999).
17. Datta, K., Bellacosa, A., Chan, T. O. & Tsichlis, P. N. Akt is a direct target of the phosphatidylinositol 3-kinase. Activation by growth factors, v-src and v-Ha-ras, in Sf9 and mammalian cells. J. Biol. Chem. 271, 30835-30839 (1996).
18. DeWire, S. M., Ahn, S., Lefkowitz, R. J. & Shenoy, S. K. β-arrestins and cell signaling. Annu. Rev. Physiol. 69, 483-510 (2007).
19. Gao, H. et al. Identification of β-arrestin2 as a G protein-coupled receptor-stimulated regulator of NF-κB pathways. Mol. Cell 14, 303-317 (2004).
20. Luan, B., Zhang, Z., Wu, Y., Kang, J. & Pei, G. β-arrestin2 functions as a phosphorylation-regulated suppressor of UV-induced NF-κB activation. EMBO J. 24, 4237-4246 (2005).
21. Kang, J. et al. A nuclear function of β-arrestin1 in GPCR signaling: regulation of histone acetylation and gene transcription. Cell 123, 833-847 (2005).
22. + T cell survival and autoimmunity by β-arrestin 1. Nature Immunol. 8, 817-824 (2007).
23. Netea, M. G. et al. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nature Med. 12, 650-656 (2006).
24. Arkan, M. C. et al. IKK-β links inflammation to obesity-induced insulin resistance. Nature Med. 11, 191-198 (2005).
25. Shen, H. Q., Zhu, J. S. & Baron, A. D. Dose-response relationship of insulin to glucose fluxes in the awake and unrestrained mouse. Metabolism 48, 965-970 (1999).
26. Haluzik, M. M. et al. Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels. Endocrinology 147, 4517-4524 (2006).